WEBINAR
Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics
Register here
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Our latest updates
Discover what’s happening at Quotient Sciences
-
AcquisitionQuotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing OrganizationQuotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
-
Jun 10ExhibitionBIO Digital 2021Schedule a partnering meeting with our drug development experts at the BIO digital event today!
-
Info SheetQuotient Sciences Corporate Brochure 2021Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Our corporate brochure provides a key summary of who we are, what we represent, our services and our marketplace differentiation.
-
Info SheetIntegrated Programs: Early DevelopmentSimplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.